Compare REAL & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | DVAX |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2019 | 2004 |
| Metric | REAL | DVAX |
|---|---|---|
| Price | $14.10 | $10.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $13.94 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 4.7M | 1.9M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $662,789,000.00 | $330,514,000.00 |
| Revenue This Year | $14.56 | $23.23 |
| Revenue Next Year | $10.14 | $16.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.30 | ★ 26.73 |
| 52 Week Low | $4.61 | $9.20 |
| 52 Week High | $16.24 | $14.63 |
| Indicator | REAL | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 50.60 |
| Support Level | $13.84 | $10.63 |
| Resistance Level | $14.89 | $11.58 |
| Average True Range (ATR) | 0.88 | 0.32 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 42.28 | 30.00 |
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.